Watchlist Price Alert

4D Molecular Therapeutics... (FDMT)

NASDAQ: FDMT · Real-Time Price · USD

3.19

0.06 (1.92%)

At close: May 15, 2025, 3:59 PM

3.20

0.41%

After-hours: May 15, 2025, 07:06 PM EDT

1.92% (1D)

Bid	3
Market Cap	147.54M
Revenue (ttm)	9K
Net Income (ttm)	-176.44M
EPS (ttm)	-3.18
PE Ratio (ttm)	-1
Forward PE	-0.83
Analyst	Buy

Ask	3.26
Volume	292,671
Avg. Volume (20D)	681,083
Open	3.10
Previous Close	3.13
Day's Range	3.03 - 3.20
52-Week Range	2.23 - 28.93
Beta	2.86

About FDMT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol FDMT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for FDMT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

4D Molecular Therapeutics has released their quartely earnings on May 8, 2025:

Revenue of $14K misses estimates by $515.67K, with -50.00% YoY decline.

EPS of -0.86 misses estimates by 0.00, with -30.30% YoY decline.

Why Price Moved

3 months ago

-13.91%

4D Molecular Therapeutics shares are trading lower... Unlock content with Pro Subscription

4 months ago

-13.77%

4D Molecular Therapeutics shares are trading lower after Leerink Partners and Morgan Stanley cut their respective price targets on the stock.

News

1 week ago · zacks.com

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.66 per share a year ago.

2 months ago · seekingalpha.com

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential to disrupt the anti-VEGF treatment paradigm for retinal diseases. The company has a strong cash position of $...